In a phase 2 clinical trial of postmenopausal patients with hormone receptor positive, HER2-negative advanced breast cancer, dovitinib combined with fulvestrant prolonged progression-free survival in patients with FGF amplification (10.9 vs. 5.5 months) [207]. This evidence concerns the gene NR4A1 and breast cancer.